Laboratoires Mayoly Spindler S.A.S.
Laboratoires Mayoly Spindler S.A.S., headquartered in France, is a prominent player in the pharmaceutical and healthcare industry. Founded in 1970, the company has established itself as a leader in the development and distribution of innovative medicinal products, particularly in the fields of gastroenterology and dermatology. With a strong presence across Europe and expanding operations in international markets, Mayoly Spindler is renowned for its unique formulations and commitment to quality. The company’s core offerings include prescription medications and over-the-counter products that address various health concerns, setting them apart through rigorous research and development. Recognised for its dedication to patient care and safety, Laboratoires Mayoly Spindler continues to achieve significant milestones, solidifying its market position as a trusted name in healthcare solutions.
DitchCarbon Score
How does Laboratoires Mayoly Spindler S.A.S.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoires Mayoly Spindler S.A.S.'s score of 29 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoires Mayoly Spindler S.A.S.'s reported carbon emissions
Laboratoires Mayoly Spindler S.A.S., headquartered in France, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets. Mayoly Spindler commits to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by approximately 48.6% by the year 2030, using 2019 as the baseline year. Additionally, the company aims to achieve a 55.0% reduction in Scope 3 emissions per million EUR value added, which encompasses emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, and end-of-life treatment of sold products. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions required to limit global warming to 1.5°C. Mayoly Spindler's commitment reflects a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratoires Mayoly Spindler S.A.S. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
